Johnson & Johnson Unveils ‘India Detects to Defeat’ Initiative to Urge for Early Lung Cancer Detection and Testing
Johnson & Johnson Unveils ‘India Detects to Defeat’ Initiative to Urge for Early Lung Cancer Detection and Testing
An illustrated booklet, created in collaboration with Amar Chitra Katha, is now available at select clinics to help patients and their loved ones better understand lung cancer
National, November 27, 2024: Johnson & Johnson (J&J) India announced the launch of its nationwide campaign, India Detects to Defeat, highlighting the critical role of early detection and testing in improving lung cancer outcomes. The first phase of this initiative features a collaboration with Amar Chitra Katha, one of India’s most beloved storytellers, to create an engaging, illustrated booklet that simplifies complex medical information.
This resource is designed to assist patients, and their families in better understanding the risks, symptoms, and importance of early diagnosis for lung cancer. Available in both print and digital formats, the booklet can be accessed at select healthcare provider (HCP) clinics or online via the J&J India website.
According to the Indian Council of Medical Research (ICMR), lung cancer cases in India are projected to rise dramatically, with a seven-fold increase anticipated by 2025[1]. In 2022 alone, approximately 81,000 cases of lung cancer were reported, along with 75,000 deaths, making it one of the leading causes of cancer-related mortality in the country[2].
India Detects to Defeat, primarily focuses on raising awareness about Non-Small Cell Lung Cancer (NSCLC), which accounts for 85% of all lung cancer cases globally as per the Lancet Regional Health - Southeast Asia 2024[3]. This type of cancer is often associated with genetic mutations, epidermal growth factor receptor (EGFR) gene, which can drive uncontrolled cell growth and division.
Awareness is the first step toward early detection, timely intervention, and improved outcomes in lung cancer care. Through this initiative, Johnson & Johnson aims to bridge the awareness gap by presenting critical information in an accessible and easy-to-understand format.
Heading the Johnson & Johnson Innovative Medicine India & South Asia operations, Pushkar Kulkarni said, “Partnering with Amar Chitra Katha in the first phase of the ‘India Detects to Defeat’ campaign, lets us spread lung cancer awareness in a way that's both accessible and memorable. Through storytelling, we simplify complex information, reaching families across India and empowering them to recognize early signs and seek timely care. This booklet is our call to action: know the signs, seek early diagnosis, consult your physician for guidance and take a stand against this silent killer. Together, we can make a real impact on early detection and save lives.”
Ms. Gayathri Chandrasekhar, Editor-in-Chief, Amar Chitra Katha (Tinkle) added, “At Amar Chitra Katha, we believe in the power of stories to inspire, educate, and bring positive change. This partnership helps us reach a broader audience, delivering a complex health message simply. Through relatable narratives, we hope to spark conversations around lung health and early detection, empowering families to make informed health decisions.”
As per the World Health Organization, lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. This disease is often diagnosed at advanced stages when treatment options are limited. Screening high risk individuals has the potential to allow early detection and to improve survival rates.
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC9629535/
[2] https://www.wcrf.org/preventing-cancer/cancer-statistics/lung-cancer-statistics/
[3] https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(24)00080-5/fulltext
Disclaimer: The information (including, without limitation, advice and recommendations) provided herein is intended solely as a general educational aid. It is not intended as medical or healthcare advice or to be used for medical diagnosis or treatment for any individual problem. It is also not intended as a substitute for professional advice and services from a qualified healthcare provider familiar with your unique facts. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition and before initiating any new treatment. Johnson & Johnson Private Limited and its agents shall not be liable in any manner whatsoever for any consequence relating directly or indirectly due to any action you take based on the information provided herein.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.jnj.com or at www.janssen.com/johnson-johnson-innovative-medicine.
Johnson & Johnson Private Limited is a Johnson & Johnson company.
© copyright 2024 of Johnson & Johnson Private Limited. All rights reserved.